Liraglutide and semaglutide improve cardiovascular and renal outcomes across most BMI categories in type 2 diabetes: results of the LEADER and SUSTAIN 6 trials

被引：0
|
作者：
Verma, S. [1 ,2 ]
Bain, S. C. [3 ]
Bhatt, D. L. [4 ,5 ]
Leiter, L. A. [1 ,2 ]
Mazer, C. D. [1 ,2 ]
McGuire, D. K. [6 ]
Pratley, R. [7 ]
Zinman, B. [8 ]
Lindberg, S. [9 ]
Rasmussen, S. [9 ]
Vrazic, H. [9 ]
Buse, J. B. [10 ]
机构：
[1] St Michaels Hosp, Toronto, ON, Canada
[2] Univ Toronto, Toronto, ON, Canada
[3] Swansea Univ, Inst Life Sci, Swansea, W Glam, Wales
[4] Brigham & Womens Hosp, Heart & Vasc Ctr, 75 Francis St, Boston, MA 02115 USA
[5] Harvard Med Sch, Boston, MA 02115 USA
[6] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[7] AdventHlth Translat Res Inst Metab & Diabet, Orlando, FL USA
[8] Univ Toronto, Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada
[9] Novo Nordisk AS, Soborg, Denmark
[10] Univ N Carolina, Sch Med, Chapel Hill, NC 27515 USA
来源：
DIABETOLOGIA | 2019年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1164
引用
收藏
页码：S560 / S560
页数：1
相关论文
共 50 条
  • [31] Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease Results of the LEADER Trial
    Verma, Subodh
    Bhatt, Deepak L.
    Bain, Stephen C.
    Buse, John B.
    Mann, Johannes F. E.
    Marso, Steven P.
    Nauck, Michael A.
    Poulter, Neil R.
    Pratley, Richard E.
    Zinman, Bernard
    Michelsen, Marie M.
    Fries, Tea Monk
    Rasmussen, Soren
    Leiter, Lawrence A.
    [J]. CIRCULATION, 2018, 137 (20) : 2179 - 2183
  • [32] Increase in pulse rate with semaglutide did not result in increased adverse cardiac events in subjects with type 2 diabetes in the SUSTAIN 6 cardiovascular outcomes trial
    Seufert, J.
    Nauck, M.
    Rosenstock, J.
    Hansen, T.
    Vrazic, H.
    Vilsboll, T.
    [J]. EUROPEAN HEART JOURNAL, 2018, 39 : 597 - 597
  • [33] Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials
    Ahren, Bo
    Atkin, Stephen L.
    Charpentier, Guillaume
    Warren, Mark L.
    Wilding, John P. H.
    Birch, Sune
    Holst, Anders Gaarsdal
    Leiter, Lawrence A.
    [J]. DIABETES OBESITY & METABOLISM, 2018, 20 (09): : 2210 - 2219
  • [34] Neutrophil to lymphocyte ratio predicts cardiovascular events in people with type 2 diabetes: Post hoc analysis of the SUSTAIN 6 and PIONEER 6 cardiovascular outcomes trials
    Verma, Subodh
    Husain, Mansoor
    Madsen, Christian M.
    Leiter, Lawrence A.
    Kuhlman, Anja Birk
    Vilsboll, Tina
    Rasmussen, Soren
    Libby, Peter
    [J]. DIABETES OBESITY & METABOLISM, 2023, 25 (08): : 2398 - 2401
  • [35] Heterogeneity in renal end points of cardiovascular outcomes trials in Type 2 diabetes
    Balijepalli, Chakrapani
    Yan, Kevin
    Zoratti, Michael
    Franklin, Meg
    Druyts, Eric
    [J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2020, 10 (03) : 169 - 173
  • [36] Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials
    Aroda, V. R.
    Ahmann, A.
    Cariou, B.
    Chow, F.
    Davies, M. J.
    Jodar, E.
    Mehta, R.
    Woo, V
    Lingvay, I
    [J]. DIABETES & METABOLISM, 2019, 45 (05) : 409 - 418
  • [37] LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations
    Daniels, G. H.
    Hegedus, L.
    Marso, S. P.
    Nauck, M. A.
    Zinman, B.
    Bergenstal, R. M.
    Mann, J. F. E.
    Karsbol, J. Derving
    Moses, A. C.
    Buse, J. B.
    Tuttle, M.
    [J]. DIABETES OBESITY & METABOLISM, 2015, 17 (05): : 477 - 486
  • [38] Linagliptin in patients with type 2 diabetes and cardiovascular and/or renal disease: results from a cardiovascular and renal outcomes trial
    Guthrie, Robert
    [J]. POSTGRADUATE MEDICINE, 2020, 132 (04) : 314 - 319
  • [39] Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials Diabetes Care 2017; 40:821-831
    Feldman-Billard, Sylvie
    [J]. DIABETES CARE, 2017, 40 (12) : E174 - E174
  • [40] Liraglutide reduces cardiovascular events and mortality in type 2 diabetes independent of LDL cholesterol and statin use: results of the LEADER trial
    Leiter, L. A.
    Verma, S.
    Mazer, C.
    Bain, S. C.
    Buse, J.
    Marso, S.
    Nauck, M. A.
    Zinman, B.
    Bosch-Traberg, H.
    Frimer-Larsen, H.
    Michelsen, M. M.
    Bhatt, D. L.
    [J]. DIABETOLOGIA, 2018, 61 : S356 - S357
12345